Israel
Enzymit, founded in 2020, is pioneering a shift in bioproduction with its innovative approach in creating novel enzymes. The company, headquartered in Israel, aims to make bioproduction faster, simpler, cost-effective, and sustainable through cell-free and synthetic biology methods, standing out within the Biotechnology, Health and Wellness, and Life Sciences industries.
By leveraging deep learning algorithms and high-throughput testing, Enzymit has positioned itself at the forefront of fine chemical manufacturing, foodtech, health, and biodefense applications. The firm's collaborative efforts with global manufacturers have expanded both its technological reach and market influence, indicating a robust growth trajectory.
In its most recent funding round, Enzymit secured a $10.00M Series A investment on 01 September 2024 from notable investors such as First Star Ventures, Grove Ventures, Khosla Ventures, and Sapir Venture Partners. This financing underscores the market's confidence in its potential to reshape production paradigms.
